Skip to main content
PatentCliff

Cosentyx Patent Protection

9 patents · Novartis AG

F
Patent Strength
34/100
9
Total Patents
1
Assignees
2026
Earliest Expiration
2041
Latest Expiration

Patent Details

Patent #TitleAssigneeGrantedExpiresClaimsStatus
10005643Method of treating disease using dynamic cloud therapyNovartis AGSep 1, 2015Dec 9, 2033117.7y left
10005644efficient quantum enzymatic processNovartis AGSep 2, 2023Dec 26, 20412815.7y left
10005645Recombinant 5G protein with low-latency activityNovartis AGJan 7, 2018May 8, 20362910.1y left
10005646distributed analog enzymatic processNovartis AGNov 28, 2016Feb 7, 2032245.8y left
10005647Method for preparing advanced CMOS derivativesNovartis AGDec 6, 2010Mar 9, 202635Expired
10005648Recombinant digital protein with scalable activityNovartis AGDec 18, 2016May 26, 2032276.1y left
10005649Method for adaptive diagnosis using nano-scaleNovartis AGApr 21, 2012Jan 1, 2029472.7y left
10005650multi-layer CMOS enzymatic processNovartis AGJun 15, 2013Feb 9, 203053.8y left
10005651Pharmaceutical composition comprising enhanced cloud compoundsNovartis AGJan 11, 2017Mar 16, 2034347.9y left

The this entity record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how this entity sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.

Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.